<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 6, 2018 (HealthDay News) — Administration of inhaled nitrite is not associated with improvement in exercise capacity compared with placebo among patients with heart failure with preserved ejection fraction (HFpEF), according to a study published in the Nov. 6 issue of the Journal of the American Medical Association<\/i>.<\/p>\n
Barry A. Borlaug, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a multicenter, two-treatment crossover trial involving 105 patients with HFpEF. Participants were randomly assigned to four weeks of inorganic nitrite or placebo administered via a micronebulizer device followed by a two-week washout period with no study drug for each six-week phase of the crossover study.<\/p>\n
The researchers observed no significant difference in mean peak oxygen consumption in the nitrite phase versus the placebo phase (13.5 versus 13.7 mL\/kg\/min; P = 0.27). No significant between-treatment phase differences were observed in daily activity levels (5,497 versus 5,503 accelerometry units; P = 0.91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 versus 61.9; P = 0.39), functional class (2.5 versus 2.5; P = 0.43), echocardiographic E\/e’ ratio (16.4 versus 16.6; P = 0.93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 versus 533 pg\/mL; P = 0.74). Worsening heart failure occurred in 2.9 and 7.6 percent of participants during the nitrite phase and placebo phase, respectively.<\/p>\n
“These results are in contrast to multiple earlier studies suggesting administration of inorganic nitrite or nitrate may have benefits in HFpEF,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical and medical device industries.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n